The anthrapyrazoles

Cancer Treatment Reviews

Volumn 21, Issue 6, 1995, Pages 541-552

  Gogas, H ^a   Mansi, J L ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; LOSOXANTRONE; OXANTHRAZOLE; PYRAZOLE DERIVATIVE; PYRAZOLONE DERIVATIVE; TELOXANTRONE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FREE RADICAL; GRANULOCYTE COLONY STIMULATING FACTOR; INTERCALATING AGENT; MITOXANTRONE;

ANIMAL; CLINICAL TRIAL; DRUG SCREENING; HUMAN; REVIEW; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CROSS RESISTANCE; DNA DAMAGE; DRUG CLEARANCE; DRUG FATALITY; DRUG MECHANISM; ERYTHEMA; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; LEUKOPENIA; LIPID PEROXIDATION; LUNG NON SMALL CELL CANCER; MELANOMA; MUCOSA INFLAMMATION; NAIL DYSTROPHY; NAUSEA; NONHUMAN; NUCLEIC ACID SYNTHESIS; PHLEBITIS; PRURITUS; STOMACH CANCER; VOMITING;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PYRAZOLES; PYRAZOLONES;

EID: 0029551591     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/0305-7372(95)90017-9     Document Type: Article

References (53)

1. 5-[(aminoalkyl)amino]-substituted-anthra[1, 9-cd] pyrazol-6(2H)-ones as novel anticancer agents
2. Mitoxantrone: Bluebeard for malignancies
3. A randomized comparison of single-agent doxorubicin and epirubicin as first line cytotoxic therapy in advanced breast cancer
4. Electron spin resonance study on the mode of generation of free-radicals of daunomycin, adriamycin and carboquone in NAD(P)Hmicrosome system
5. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin
6. The mechanism of action of quinone antibiotics
7. Enzymatic defences of the mouse heart against reactive oxygen metabolites
8. Diminished superoxide anion generation by reduced 5-iminodaunorubicin relative to daunorubicin and the relationship to cardiotoxicity of the anthracycline antitumor agents
9. Metabolic disposition of 5-iminodaunorubicin in the rat
10. Characteristics of the interaction of anthrapyrazole anti-cancer deoxyribonucleic acids
11. In vitro DNA strand scission and inhibition of nucleic acid synthesis in L1210 leukaemia cells by a new class of DNA complexes the anthra[1, 9-cd] pyrazol-6(2H)-ones (anthrapyrazoles)
12. The effect of the anthrapyrazole anti-tumor agent CI941 on rat liver microsome and cytochrome p-450 reductase mediated free radical processes
13. Cardiotoxic potential of substituted [1, 9-cd] pyraxol-6-(2H)-ones (anthrapyrazoles) as assessed by the fetal mouse heart organ culture
14. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors
15. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukaemia cells
16. Anthrapyrazole and amascrine analogues in mouse and human leukaemia in vitro and in vivo
17. Patterns of cross-resistance in a multidrug-resistant small cell lung carcinoma cell line
18. Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modifications by verapamil and cyclosporin A
19. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients
20. Pharmacological studies with the anthrapyrazole CI 941: a new DNA complexing drug
21. Acute intravenous toxicity of CI 937 on anthrapyrazole anticancer drug candidate
22. Toxicology evaluation of CI 937, an anthrapyrazole anticancer agent, in rats
23. 2F mice and toxicity studies in beagle dogs and Fischer rats of anthrapyrazole (NSC-349174)
24. Preclinical pharmacology of the anthrapyrazole analogue oxantrazole (NSC-349174, Piroxantrone)
25. Phase I study and pharmacodynamics of piroxantrone (NSC 349174) a new anthrapyrazole
26. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole)
27. Phase I study of high dose piroxantrone with granulocyte colony-stimulating factor
28. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocytecolony stimulating factor
29. Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology
30. Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation
31. A phase I study of high dose DuP 941 (losoxantrone) in combination with cyclophosphamide (CTX)
32. Phase I pharmacokinetic and pharmacodynamic study of a new anthrapyrazole CI-937 (DuP 937)
33. Phase I pharmacokinetic study of Dup 937, a new anthrapyrazole
34. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results
35. Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung
36. Phase II trial of piroxantrone in gastric carcinoma
37. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas
38. Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck
39. A Phase II trial of piroxantrone in adenocarcinoma of the pancreas
40. Phase II evaluation of piroxantrone in renal cell carcinoma
41. Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy
42. Anthrapyrazole CI 941: a highly active new agent in the treatment of advanced breast cancer
43. Phase II study of losoxantrone in previously treated and untreated patients with advanced breast cancer (CA)
44. A phase II multicentre trial of losoxantrone (DuP-941) in patients with metastatic hormone-refractory prostate cancer (HRPC)
45. Phase II study on DuP 937 (teloxantrone) in colorectal carcinoma
46. A phase II trial of DuP 937 (teloxantrone) in non small cell lung cancer
47. A phase II study of DuP 937 (teloxantrone) in metastatic malignant melanoma
48. A phase II study of DuP 937 in small cell (SCLC) and non-small cell (NSCL) lung cancer
49. A phase II study of DuP 937 in GI cancers
50. A phase II study of DuP 937 in head and neck (H/N) cancer
51. A phase II study of DuP 937 in advanced breast cancer
52. Combination chemotherapy and adriamycin in patients with advanced breast cancer
53. A randomised trail comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer